Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | AlteredExpression | disease | BEFREE | However, when comparing Bcl-2 expression and known survival mean of the patients, significant differences were observed (p<0.001) so that mean survivals were 31.1, 24.4, 52.2 and 54.1 months respectively for NPC patients with -, +, ++ and Bcl-2 immunoreactivity. | 9046038 | 1997 | ||||
|
0.100 | Biomarker | disease | BEFREE | Furthermore, we detected miR-29c repressed expression of anti-apoptotic factors, Mcl-1 and Bcl-2 in NPC tissues and cell lines. | 23142283 | 2013 | ||||
|
0.100 | Biomarker | disease | BEFREE | Antibody against the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2, in patients with nasopharyngeal carcinoma. | 9783682 | 1998 | ||||
|
0.100 | AlteredExpression | disease | BEFREE | Although no direct correlation between the sensitivity to TRAIL and the relative expression levels of Bcl-2 and activated Akt was found in the NPC cell lines examined, siRNA mediated the downregulation of Bcl-2 and LY294002-induced inactivation of Akt, increasing the sensitivity of all examined NPC cell lines to TRAIL. | 22322844 | 2012 | ||||
|
0.100 | Biomarker | disease | BEFREE | All cases of undifferentiated NPC were positive for Bcl-2 but only one BHRF1 positive cell was identified in 1 of 39 cases of primary undifferentiated NPC. | 11505451 | 2001 | ||||
|
0.100 | Biomarker | disease | BEFREE | ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma. | 30017199 | 2018 | ||||
|
0.100 | AlteredExpression | disease | BEFREE | Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. | 8380056 | 1993 | ||||
|
0.100 | AlteredExpression | disease | BEFREE | Bcl-2 is an antiapoptotic gene overexpressed in many tumors, including nasopharyngeal carcinoma (NPC). | 25405832 | 2014 |